The estimated Net Worth of Richard E. Russell is at least $138 mil dollars as of 12 December 2019. Richard Russell owns over 3,113 units of Minerva Neurosciences Inc stock worth over $90,166 and over the last 7 years Richard sold NERV stock worth over $47,910.
Richard has made over 2 trades of the Minerva Neurosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Richard sold 3,113 units of NERV stock worth $23,098 on 12 December 2019.
The largest trade Richard's ever made was selling 3,117 units of Minerva Neurosciences Inc stock on 11 December 2018 worth over $24,811. On average, Richard trades about 1,246 units every 73 days since 2017. As of 12 December 2019 Richard still owns at least 33,770 units of Minerva Neurosciences Inc stock.
You can see the complete history of Richard Russell stock trades at the bottom of the page.
Richard's mailing address filed with the SEC is 1601 Trapelo Rd #284, Waltham, MA 02451, USA.
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... y Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include: